Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis.
There is emerging evidence for the existence of secretory pathways for superoxide dismutase (SOD1) mutants linked to amyotrophic lateral sclerosis (ALS) and for neurotoxicity of extracellular mutant SOD1. This evidence led us to test immunization protocols aiming to reduce the burden of extracellular SOD1 mutants in nervous tissue of mice models of ALS, by using bacterially purified recombinant SOD1 mutant protein as an immunogen. First, a vaccination was tested on a G37R SOD1 mouse strain with late-onset disease exhibiting levels of mutant SOD1 protein at 4-fold higher than normal SOD1 levels. Repeated injections of adjuvant/SOD1 mutant with a final booster injection before symptoms at 6 months of age were effective in delaying disease onset and extending the life span of G37R SOD1 mice by >4 weeks. Western blot analysis with a monoclonal antibody specific to mutant SOD1 forms provided evidence of clearance of SOD1 species in the spinal cord of vaccinated G37R SOD1 mice. In contrast, this vaccination approach failed to confer significant protection in G93A SOD1 mice with extreme overexpression of mutant SOD1. Nonetheless, a passive immunization through intraventricular infusion of purified anti-human SOD1 antibody with osmotic minipump succeeded in alleviating disease symptoms and prolonging the life span of G93A SOD1 mice. From these results, we propose that immunization strategies should be considered as potential avenues for treatment of familial ALS caused by SOD1 mutations.
Urushitani
Makoto
M
Department of Anatomy and Physiology, Laval University Research Centre, Centre Hospitalier de l'Université Laval, 2705 Boulevard Laurier, Québec QC G1V 4G2, Canada.
Ezzi
Samer Abou
SA
Julien
Jean-Pierre
JP
D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy*; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D007114:Immunization / Q000379:methods*; D051379:Mice; D020125:Mutation, Missense; D011994:Recombinant Proteins; D013482:Superoxide Dismutase / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome
D000906:Antibodies; D011994:Recombinant Proteins; D013482:Superoxide Dismutase